Evidence on pharmacological agents for treating bony defects in chronic periodontitis: A network meta-analysis
Abstract
Background: Chronic periodontitis is an infectious disease of the oral cavity that causes progressive destruction of periodontal tissues, leading to structural changes like attachment loss, bone resorption, resulting in bony defects, and potential tooth loss if left untreated. Effective drugs, such as alendronate, rosuvastatin (RSV), atorvastatin, melatonin, and metformin (MF), have been used as adjuncts to scaling and root planning and require evaluation for their comparative effectiveness in treating bony defects in patients with chronic periodontitis. This study aims to compare the effectiveness of these drugs for treating such defects.
Materials and methods: This network meta-analysis (NMA) was conducted following Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines and registered in PROSPERO (CRD42024600432). A comprehensive search of PubMed, Scopus, and Cochrane Library identified 11 eligible randomized clinical trials reporting changes in clinical attachment level (CAL) and bone fill (BF) at 6 months posttreatment. The NMA systematically compared treatment outcomes across different intervention groups.
Results: MF was the most effective treatment for CAL and BF at 6 months. Ranking probabilities indicated that MF and RSV had the highest likelihood of being the most effective treatments.
Conclusion: These findings from the NMA suggest that MF may be an effective option for CAL improvement and BF. Further research is needed to validate these…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.